Hikma Pharmaceuticals Plc Directorate Change (3942L)
30 Aprile 2020 - 8:00AM
UK Regulatory
TIDMHIK
RNS Number : 3942L
Hikma Pharmaceuticals Plc
30 April 2020
Hikma appoints Douglas Hurt as Director
London, 30 April 2020 - Hikma Pharmaceuticals PLC (LSE: HIK)
(DIFX: HIK) ( Hikma ) announces the appointment of Douglas Hurt as
an independent non-executive director effective 1 May 2020. Over
the course of 2020, Douglas will assume responsibility for chairing
the Audit Committee.
'I am very pleased that Douglas will be joining Hikma's Board.
He brings a wealth of experience, particularly in relation to
operational and financial management, reporting, risk and
leadership of audit committees.' said Said Darwazah, Executive
Chairman. 'Over the course of 2020, we will undertake the
transition of the Audit Committee chair to Douglas and the role of
Senior Independent Director to Pat Butler .'
During his executive career, Douglas served as Finance Director
of IMI plc, the global engineering group, from 2006 to 2015. Prior
to this, he held a number of senior finance and general management
positions at GlaxoSmithKline plc, which he joined in 1983,
previously having worked at Price Waterhouse. His career has
included several years working in the US as the Chief Financial
Officer and significant experience in European businesses as an
Operational and Regional Managing Director.
Douglas is the Senior Independent Director and Chairman of the
Audit Committee at Vesuvius PLC and Countryside Properties PLC. He
is a non-executive director and Chairman of the Audit Committee of
the British Standards Institution. Douglas served as Senior
Independent Director and Chairman of the Audit Committee of Tate
& Lyle plc until July 2019.
Douglas is a Chartered Accountant and holds an MA(Hons) in
Economics from Cambridge University.
-- ENDS --
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs, Company Secretary +44 (0)20 7399 2772
Susan Ringdal, EVP Strategy and Global Affairs +44 (0)20 7399
2760
About Hikma
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
more than 40 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we're a global company with a local presence across the
United States (US), the Middle East and North Africa (MENA) and
Europe, and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,500 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner in the MENA region, and through our
venture capital arm, are helping bring innovative health
technologies to people around the world. For more information,
please visit www.hikma.com .
LEI: 549300BNS685UXH4JI75
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAPPUGCCUPUGMB
(END) Dow Jones Newswires
April 30, 2020 02:00 ET (06:00 GMT)
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Apr 2023 a Apr 2024